|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
MONEY FLOW INDEX
Trading: HOLD @ $3.61
Signal Strength: MEDIUM
Opthea (ASX:OPT) current trading has maintained the money flow index oversold status and signalled the continuation of the bullish trading conditions. Currently, the MFI is 84.36. The bullish signal has been active for 0 days. During the quarter, the lowest MFI value was 53.52.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. Indicator can be applied to the short/medium term timeframe, but the best results are obtained with larger cyclical swings in-line with the trend direction. This accumulation / distribution oscillator can provide guidance on the money flow direction from the companies recent trading.
Money Flow Index (MFI) is a volume-based indicator it could be used in technical analysis to measure the strength of money flow in and out of a security index and market. The principle of MFI calculation is a comparison of positive money flow to negative money flow. MFI is also known as volume-weighted RSI. MFI starts with the typical price for each period. The same as RSI the MFI scale is between 0 and 100.
Calculation: Money Flow Index (MFI):
1) Typical Price = (High + Low + Close)/3;
2) Raw Money Flow = Typical Price x Volume;
3) Money Flow Ratio = (14-period Positive Money Flow)/(14-period Negative Money Flow);
4) Money Flow Index = 100 - 100/(1 + Money Flow Ratio)
PROFILE: Opthea (OPT.AX)
Stock Exchange: ASX
Ticker Codes: | OPT.AX | ASX:OPT |
Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.
|MVP Medical Developments||10.28||8.8||674,204||39.55||NEUTRAL|
|DOW Downer EDI||7.6||6||10,946,339||55.44||NEUTRAL|
|FBR Fastbrick Robotics||0.06||5.8||881,024||51.01||NEUTRAL|
|MNS Milnes Holdings||0.11||4.8||239,846||45.73||NEUTRAL|
|HFR Highfield Resources||0.8||4.6||86,664||52.94||NEUTRAL|
|VRL Village Roadshow||4.02||4.4||636,398||26.05||NEUTRAL|
|PNI Pinnacle Investment Management||4.81||4.3||558,446||72.72||NEUTRAL|